Journal for ImmunoTherapy of Cancer: 12 (9)

Commentary

scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC (4 September, 2024)
Qi Peng, Yuanyuan Xu, Xinsheng Yao

Editorial

Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family (10 September, 2024)
Jason John Luke, Omid Hamid, Bernard A Fox, Paolo A Ascierto, Iman Osman, James J Mule, Pedro J Romero, Michael T Lotze

Basic tumor immunology

Original research: Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade (28 September, 2024)
Nicola Principe, Amber-Lee Phung, Kofi L P Stevens, Omar Elaskalani, Ben Wylie, Caitlin M Tilsed, Fezaan Sheikh, M Lizeth Orozco Morales, Joel Kidman, Elly Marcq, Scott A Fisher, Anna K Nowak, Alison M McDonnell, W Joost Lesterhuis, Jonathan Chee
Original research: Inhibition of the NF-κB/HIF-1α signaling pathway in colorectal cancer by tyrosol: a gut microbiota-derived metabolite (28 September, 2024)
Jian Guo, Fanqi Meng, Ruixue Hu, Lei Chen, Jiang Chang, Ke Zhao, Honglin Ren, Zengshan Liu, Pan Hu, Guangyi Wang, Jiandong Tai
Original research: Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers (24 September, 2024)
Khaldoun Gharzeddine, Cristina Gonzalez Prieto, Marie Malier, Clara Hennot, Renata Grespan, Yoshiki Yamaryo-Botté, Cyrille Y Botté, Fabienne Thomas, Marie-Hélène Laverriere, Edouard Girard, Gael Roth, Arnaud Millet
Original research: Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer (18 September, 2024)
Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana S Mauldin, Kate A Goundry, Gabriel F Hanson, Mahdin Hossain, Chad Lehman, Ryan D Gentzler, Nolan A Wages, Craig L Slingluff, Timothy N J Bullock, Sepideh Dolatshahi, Michael G Brown
Original research: S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling (11 September, 2024)
Feyza Gül Özbay Kurt, Beatrice-Ana Cicortas, Bianca M Balzasch, Carolina De la Torre, Volker Ast, Ece Tavukcuoglu, Cagla Ak, Sebastian A Wohlfeil, Adelheid Cerwenka, Jochen Utikal, Viktor Umansky
Original research: Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway (4 September, 2024)
Zelin Hou, Fengchun Lu, Jiajing Lin, Yuwei Wu, Linjin Chen, Haizong Fang, Linlin Chen, Shihan Zhang, Heguang Huang, Yu Pan

Clinical/translational cancer immunotherapy

Original research: Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study (30 September, 2024)
Idris Bahce, Chris Dickhoff, Famke L Schneiders, Joris Veltman, David J Heineman, Sayed M S Hashemi, Anne Vrijmoet, Ilias Houda, Ezgi B Ulas, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Lilian J Meijboom, Daniela E Oprea-Lager, Febe van Maldegem, Marieke F Fransen, Tanja D de Gruijl, Teodora Radonic, Suresh Senan
Original research: Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors (28 September, 2024)
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan, Silvana Bucur, Hye Sung Kim, Liam IL-Young Chung, Christine McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles Blanke, Razelle Kurzrock
Original research: MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors (23 September, 2024)
Si Chen, Jiakai Hou, Roshni Jaffery, Ashley Guerrero, Rongjie Fu, Leilei Shi, Ningbo Zheng, Ritu Bohat, Nicholas A Egan, Chengtai Yu, Sana Sharif, Yue Lu, Wei He, Shuyue Wang, Donjeta Gjuka, Everett M Stone, Pooja Anil Shah, Jordi Rodon Ahnert, Taiping Chen, Xinli Liu, Mark T Bedford, Han Xu, Weiyi Peng
Original research: MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers (6 September, 2024)
Iñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, María Campos, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Carlos E De Andrea, Laura Álvarez-Gigli, Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed
Original research: Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models (5 September, 2024)
Dan Mei, Ziyang Xue, Tianjing Zhang, Yining Yang, Lin Jin, Qianqian Yu, Jian Hong, Xianzheng Zhang, Jinru Ge, Li Xu, Han Wang, Ziwei Zhang, Yuchen Zhao, Yuanfang Zhai, Qianshan Tao, Zhimin Zhai, Qingsheng Li, Hongxia Li, Lingling Zhang
Original research: Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma (5 September, 2024)
Tanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Nikhil I Khushalani, Kenneth Y Tsai, Andrew S Brohl
Original research: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy (3 September, 2024)
Yanyang Nan, Yu Bai, Xiaozhi Hu, Kaicheng Zhou, Tao Wu, An Zhu, Mengyang Li, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Shuwen Xu, Yuanzhen Zhang, Jun Lin, Xian Zeng, Jiajun Fan, Xuyao Zhang, Xuebin Wang, Dianwen Ju

Immune cell therapies and immune cell engineering

Original research: Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy (26 September, 2024)
Jessie S Kroonen, Anne K Wouters, Ilona J de Graaf, Dennis F G Remst, Sumit Kumar, Tassilo L A Wachsmann, Amina F A S Teunisse, Jessica P Roelands, Noel F C C de Miranda, Marieke Griffioen, Mirjam H M Heemskerk, Alfred C O Vertegaal
Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy (24 September, 2024)
Marion Larue, Amélie Bouvier, Alexis Maillard, Alexis Cuffel, Vincent Allain, Renata Ursu, Antoine F Carpentier, Elie Azoulay, Catherine Thieblemont, Roberta Di Blasi, Sophie Caillat-Zucman
Original research: BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma (23 September, 2024)
Ting Wang, Yazi Yang, Lie Ma, Ru Feng, Jiangtao Li, Chunli Zhang, Jiefei Bai, Yanping Ding, Guanghua Liu, Fei Wu, Xinan Lu, Shi Feng, Zhenling Li, Ting He, Jian Li, Hui Liu
Original research: Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy (12 September, 2024)
Wen Luo, Hai Hoang, Hongwen Zhu, Katherine Miller, Xiaokui Mo, Shiori Eguchi, Meijuan Tian, Yanling Liao, Janet Ayello, Jeremy M Rosenblum, Mario Marcondes, Mark Currier, Elaine Mardis, Timothy Cripe, Dean Lee, Mitchell S Cairo
Original research: Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus (11 September, 2024)
Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Long Chen, Muna Igboko, Rosa Nadal, Gang Zeng, Gordon Parry, David F Stroncek, Steven Highfill, Annika V Dalheim, Robert Reger, Michael I Nishimura, Richard W Childs

Immunotherapy biomarkers

Original research: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses (28 September, 2024)
Nathan D Seligson, James L Chen, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell, Allison L Richards, Cristina R Antonescu, David A Liebner, Mohammed M Milhem, Howard Streicher, William D Tap, Gary K Schwartz, Suzanne George, Sandra P D'Angelo
Original research:
Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8⁺ T cell infiltration
(10 September, 2024)
Lunbiao Gan, Tong Lu, Yu Lu, Hongtao Song, Jiayu Zhang, Keying Zhang, Shiqi Lu, Xinjie Wu, Fengze Nie, Sijia Di, Donghui Han, Fa Yang, Weijun Qin, Weihong Wen
Original research: Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade (6 September, 2024)
Jie Mei, Jiahui Chu, Kai Yang, Zhiwen Luo, Jiayue Yang, Junying Xu, Qing Li, Yan Zhang, Qinglin Zhang, Mengyun Wan, Ningyi Xue, Junli Ding, Yichao Zhu, Yun Cai, Yongmei Yin
Original research:
Intratumoral CXCL13⁺ CD160⁺ CD8⁺ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer
(6 September, 2024)
Jiawei Wang, Yuan Liang, Ao Xue, Jian Xiao, Xinyu Zhao, Shuqing Cao, Pengyu Li, Jiacheng Dong, Yuan Li, Zekuan Xu, Li Yang
Original research: Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study (3 September, 2024)
Guanchao Ye, Guangyao Wu, Yu Qi, Kuo Li, Mingliang Wang, Chunyang Zhang, Feng Li, Leonard Wee, Andre Dekker, Chu Han, Zaiyi Liu, Yongde Liao, Zhenwei Shi

Letter

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy (25 September, 2024)
Xuewei Wu, Jingjing You, Shuixing Zhang, Bin Zhang

Main menu

Table of contents

September 2024 - Volume 12 - 9

Commentary

Editorial

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

September 2024 - Volume 12 - 9

Commentary

Editorial

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter